Engflag

Oxycodon-HCI AL

Quick links to important sections

Oxycodon-HCI AL

Oxycodon-HCI AL_EN

Method of action: Analgesic

Treatment option: Pain, Cancer

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxycodon-HCI AL

Property Description
Active ingredient Oxycodone hydrochloride
Form Prolonged-release tablet (Oral)
Pharmacological class Opioid analgesic
General purpose Pain management
Origin Semisynthetic opioid (Derived from thebaine)

What Type of Medicine is Oxycodon-HCI AL?

Oxycodon-HCI AL is chemically defined as a single-substance product whose active component is Oxycodone hydrochloride, placing it within the potent pharmacological class of opioid analgesics. This medicine is subject to strict control and is designated as prescription-only.

The active substance, oxycodone, is characterized as a semisynthetic opioid, meaning it is chemically manufactured from thebaine, a natural alkaloid found in the opium poppy. This substance is recognized for its central action in pain pathways. The AL designation identifies the specific manufacturer or marketing authorization holder.

Composition and Form: Understanding Oxycodone Hydrochloride

Oxycodon-HCI AL is commonly supplied in the dosage form of an oral, prolonged-release tablet, designed to provide a steady and consistent analgesic effect over an extended duration. The product uses Oxycodone hydrochloride, a stable salt form of oxycodone, selected to ensure reliable absorption following oral administration.

The prolonged-release tablet is constructed using specialized excipients—the inert materials within the tablet—that regulate the rate at which the oxycodone is released into the body. This controlled mechanism differentiates the sustained-release formulation from immediate-release tablets, minimizing concentration fluctuations. This sustained release helps provide consistent relief over the treatment period.

General Purpose: How Does Oxycodone Work for Pain?

The general purpose of Oxycodon-HCI AL is to provide effective analgesia by modulating the transmission of pain signals in the central nervous system, thereby supporting general pain management. This medicine works by acting as an agonist, meaning it actively attaches to specific communication points known as opioid receptors—primarily mu-receptors—located in the brain and spinal cord. This action alters the transmission and perception of pain signals, which is clinically recognized for providing effective mitigation of chronic or severe pain. The resulting analgesic effect is the primary benefit of the medication in situations requiring consistent pain relief.

Regulatory References

  1. Oxycodone on WHO Essential Medicines List

What side effects are possible with Oxycodon-HCI AL?

Possible Side Effects and Safety Information

This information details the officially documented adverse reactions and safety constraints for Oxycodone Hydrochloride, based on regulatory labeling.

Adverse Reactions Scope

The most common adverse reactions reported include constipation, nausea, vomiting, drowsiness (somnolence), and dizziness. These are typically classified as Very Common or Common.

Side effects are categorized by the body system affected, including Gastrointestinal Disorders (e.g., dry mouth, abdominal pain), Nervous System Disorders (e.g., headache, confusion), and Psychiatric Disorders (e.g., insomnia, anxiety).

Serious Adverse Reactions and Safety Constraints

The most serious documented risk is life-threatening respiratory depression, which is the greatest risk during therapy initiation or following a dosage increase. Other serious reactions include severe hypotension, adrenal insufficiency with prolonged use, and Serotonin Syndrome when used with certain other medications.

Safety constraints prohibit use in patients experiencing significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, or known/suspected gastrointestinal obstruction. Concomitant use with other Central Nervous System (CNS) depressants (like benzodiazepines or alcohol) is restricted due to the heightened risk of profound sedation, coma, and death.

Duration-Related Patterns: Long-term use is associated with the risk of physical dependence and potential hormonal changes. Abrupt cessation in physically dependent patients can cause serious withdrawal symptoms.

Population-Specific Considerations: Patients who are elderly, debilitated, or have renal or hepatic impairment may be at increased risk of adverse effects and often require close monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on overdose is derived strictly from government regulatory documentation for the active ingredient, Oxycodone hydrochloride.

Documented Manifestations of Overdose

Overdose with this medication is primarily indicated by severe Central Nervous System (CNS) and Respiratory Depression. Official regulatory labels describe symptoms including:

  • Respiratory System: Slowed, shallow, or difficult breathing, culminating in apnea (long pauses between breaths).
  • Neurological: Excessive sleepiness (somnolence), progressing to profound sedation and unresponsiveness (coma).
  • Other Clinical Signs: Pinpoint pupils (miosis), skeletal muscle flaccidity, bradycardia (slowed heartbeat), and hypotension (low blood pressure).

Required Emergency Actions

The most serious, potentially fatal outcome is life-threatening respiratory depression. Regulatory agencies mandate the following immediate action:

Emergency Requirement Action Stated in Official Documents
Urgent Medical Help Seek immediate medical attention or call emergency services (e.g., 911) at once.
Antidote The specific antagonist naloxone is necessary to reverse the effects of overdose.

Close monitoring and supportive treatment, including airway management and often hospital admission, are required, particularly due to the prolonged-release nature of the tablet.

Population-Specific Notes

The risk of life-threatening respiratory depression is documented to be increased in elderly patients, cachectic or debilitated patients, and individuals with chronic pulmonary disease.

Therapeutic Uses of Oxycodon-HCI AL

What Oxycodon-HCI AL Treats: Main Uses and Benefits

Oxycodon-HCI AL is classified as an opioid analgesic and is relevant for easing symptoms related to physical discomfort in clinical scenarios where symptoms are constant, unremitting, and create noticeable physiological strain. This type of medication is used in conditions characterized by periods of heightened symptoms that necessitate continuous support and for which alternative options are inadequate. The prolonged-release form assists with maintaining functional stability during symptomatic phases, and may be part of symptomatic management strategies.

This medication is applied in the context of conditions characterized by periods of heightened symptoms, including malignant disease (cancer-related pain) and certain severe non-cancer pain states.

“Its main use helps patients cope more steadily with symptom fluctuations, by contributing to sustained symptom management.”

Oxycodon-HCI AL is commonly used to help with pronounced symptoms that have been poorly controlled by non-opioid medications, or is relevant for easing symptoms related to physical discomfort during the recovery phase following major surgery or trauma. The continuous approach contributes to easing the overall symptom load and may assist patients with coping more steadily with symptom fluctuations.

Quick Fact: Focus on Persistent Symptoms
It is relevant for easing symptoms related to physical discomfort that require supportive symptom management throughout the day, such as chronic severe pain or sustained recovery pain.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Oxycodon-HCI AL is an opioid analgesic, and its eligibility for use is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditional use for specific populations.

Who Must Not Use (Contraindicated)

Use is strictly prohibited in patients presenting with:

  • Significant respiratory depression or acute/severe bronchial asthma.
  • Known or suspected gastrointestinal obstruction, including paralytic ileus.
  • Severe Chronic Obstructive Pulmonary Disease (COPD), Cor Pulmonale, or circulatory shock.
  • Documented hypersensitivity to oxycodone.

Populations with Conditional Use

Specific restrictions apply to the following groups:

Population Group Regulatory Status
Hepatic or Renal Impairment Use requires caution; dosage initiation must be reduced.
Pediatric Patients Not recommended for children under 12 years; limited to opioid-tolerant patients aged 11 or older (FDA).
Elderly/Debilitated Requires caution; use must be initiated conservatively.
Pregnancy Prolonged use is associated with the risk of Neonatal Opioid Withdrawal Syndrome (NOWS).
Lactation Not recommended due to excretion into breast milk.

Eligibility is defined by regulatory bodies based on these critical physiological and clinical factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes clinically significant interactions with several categories of medicinal products, primarily based on effects on metabolism and central nervous system (CNS) function. The concurrent use of Oxycodon-HCI AL with strong inhibitors of the CYP3A4 enzyme, such as ketoconazole or clarithromycin, increases the concentration of oxycodone in the body, which requires careful monitoring by a healthcare professional. Conversely, strong CYP3A4 inducers, like rifampicin, can decrease oxycodone concentrations, potentially reducing its effectiveness.

A critical interaction domain involves medicines that also depress the CNS. Concomitant use with alcohol, benzodiazepines, or other sedatives has an additive pharmacodynamic effect, increasing the risk of severe respiratory depression, profound sedation, and coma. Due to this risk, concurrent prescribing with benzodiazepines should be reserved only for cases where alternative treatment options are inadequate.

Additional interactions exist with serotonergic medicines, such as selective serotonin reuptake inhibitors (SSRIs), which carry a documented risk of Serotonin Syndrome. Use with Monoamine Oxidase Inhibitors (MAOIs) is officially restricted and contraindicated. Furthermore, anticholinergic agents can increase the risk of severe constipation or paralytic ileus when used together with this medicine.

Mechanism of Action

Oxycodone is a mu-opioid receptor (MOR) agonist primarily targeting the central nervous system (CNS) and gastrointestinal tract (GIT). Following administration, oxycodone crosses the blood-brain barrier and binds stereoselectively to the MOR, a G-protein coupled receptor (GPCR). This binding induces a conformational change in the receptor, leading to the activation of the associated Gi/o protein complex.

Activation of the Gi/o protein initiates several intracellular downstream cascades. Specifically, it inhibits adenylyl cyclase, which results in a reduction of intracellular cyclic adenosine monophosphate (cAMP) levels. Concurrently, the activated Gi/o protein promotes the opening of G-protein-coupled inwardly rectifying potassium channels (GIRK), leading to potassium efflux and neuronal hyperpolarization. Furthermore, it inhibits voltage-gated calcium channels, reducing Ca^2+ influx.

These combined molecular and cellular effects decrease neuronal excitability and neurotransmitter release, particularly from primary afferent neurons in the spinal cord and periaqueductal gray matter. The system-level physiological consequence is a broad modulation of neurotransmission within the pain matrix, including the spinal cord, brainstem, and cerebral cortex, as well as a decrease in propulsive peristalsis in the GIT.

Dosage and Administration Information

Administration Scope

Feature Guideline
Route of administration Oral use only for the prolonged-release tablet formulation.
Dosing schedule The initial dose for opioid-naïve adults is typically 10 mg every 12 hours. The dosage is individualized based on response, and titration should occur no more frequently than every 24 to 48 hours to achieve pain control.
Timing in relation to meals (if applicable) The tablet may be taken with or independent of meals (with or without food).
Preparation requirements (if applicable) The tablet must be swallowed whole immediately after being placed in the mouth and taken with a sufficient amount of water.
Age-group administration rules Use in pediatric patients is restricted to those 11 years or older who are already receiving and tolerating an equivalent minimum daily dose of oxycodone. For patients with hepatic or renal impairment, the initial dose is typically reduced by 50% and titrated carefully.
Missed-dose rules If a dose is missed, the patient should generally take the next dose at the regularly scheduled time and should not take a double dose.
Special procedural conditions Doses greater than 80 mg per day are reserved for patients with established opioid tolerance. The dose must be slowly lowered (tapered) when discontinuing the medication after prolonged use.

Instruction Classifications (High-Level)

Feature Classification
Administration method type Oral
Frequency pattern Fixed, twice daily (every 12 hours)
Use-context constraints Fixed schedule for continuous administration; high doses require opioid tolerance.

Resulting Procedural Structure

Official step sequence:

  • Swallow the tablet whole.
  • Take the tablet with a sufficient amount of water.
  • Administer the dose on a fixed schedule every 12 hours.
  • Do not cut, crush, chew, or dissolve the tablet.

Connection to the overall use protocol (2–4 sentences): The instruction set defines the use of the medicine as a continuous, fixed-schedule treatment to ensure consistent delivery of the active substance over time. The mandatory requirement to swallow the tablet intact is a critical procedural step directly tied to preserving the controlled-release mechanism.

Recent Clinical Evidence

Research evidence / Overview of studies for Oxycodon-HCI AL

Evidence for Severe Pain Management

The research base for this prolonged-release formulation was studied for continuous, severe physical discomfort, relying primarily on short-term randomized controlled trials (RCTs). These trials examined outcomes reflecting daily functioning and pain intensity in adults with chronic pain. Findings describe patterns observed when the formulation was compared to inactive placebos and immediate-release oxycodone; comparative evidence reported comparable measurements of symptom reports in the short term.

For severe pain associated with malignant disease, research included RCTs and systematic reviews that explored outcomes related to perceived discomfort and quality of life. Systematic reviews of these comparative trials described that the included studies reported no significant difference in measurements between this medicine and other strong opioid medications (such as morphine or hydromorphone).

Limitations and Population Studies

A key limitation is that the evidence is primarily focused on the short term. While rigorous controlled trials provided initial data, long-term effects are not fully established by high-certainty research. The available information regarding patterns of use over a year or more primarily comes from less-controlled, observational settings. Systematic reviews indicate evidence is limited for outcomes reflecting daily functioning over many years.

The use of the formulation was evaluated in several specific patient groups, including older adults in observational studies and opioid-tolerant pediatric patients aged 11 years and older. However, the data for certain groups remain insufficient, as controlled trials often excluded patients with multiple complex medical issues. Therefore, research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

How should Oxycodon-HCI AL be stored and disposed of?

Official Storage and Disposal Requirements

Oxycodone Hydrochloride (Oxycodon-HCI AL) is a potent opioid and a federally controlled substance, requiring strict adherence to regulatory storage and disposal protocols.

Storage Conditions

Requirement Description
Temperature Store at controlled room temperature, typically below 25,^circmathrmC. Do not freeze.
Protection Keep the medicine in its original outer carton or packaging to protect it from light. Containers must remain tightly closed.
Security Keep the product out of sight and reach of children and store securely to prevent theft or diversion.

Disposal Protocol

Unused or expired oxycodone must be destroyed immediately to mitigate the risk of accidental ingestion.

Requirement Protocol
Disposal Method The best method is to use a drug take-back program or an authorized collector.
Life-Threatening Risk If no take-back option is immediately available, the FDA requires flushing the medicine down the toilet to rapidly remove the severe risk of accidental poisoning.
Stability For some solutions, the shelf-life after opening may be limited (e.g., 1 month); any unused portion of opened injectable formulations must be discarded immediately.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

Equivalent of Oxycodon-HCI AL found in:

A-Z Index: